The fiscal year 2025 concluded with a dramatic reshaping of the pharmaceutical industry’s top echelons, marked by intense competition at the very pinnacle of drug sales. While Merck’s stalwart immuno-oncology drug Keytruda maintained its position as the leading brand globally, achieving $31.68 billion in sales, a significant molecular-level shift saw Eli Lilly’s tirzepatide (marketed as Mounjaro and Zepbound) and Novo Nordisk’s semaglutide (Ozempic and Wegovy) collectively surpass its revenue. This dynamic highlights an industry in flux, where established therapeutic areas continue to thrive even as new categories experience explosive growth, driven by unprecedented demand and therapeutic breakthroughs.
Beyond the headline-grabbing contest at the top, the FY2025 data, meticulously compiled from primary filings of the Pharma 50 companies, reveals a landscape where scaled specialty franchises are not merely holding steady but actively compounding their growth. Immunologicals, in particular, stood out as a robust growth engine, expanding by an impressive 20.6% year-over-year. This expansion occurred despite an overall contraction observed within the broader pharmaceutical pipeline during the same period, signaling a strategic focus and successful market penetration within this specialized therapeutic domain. The detailed ranking below provides a comprehensive snapshot of the top-selling drugs, with currency conversions applied where necessary using specified IRS rates to ensure a standardized U.S. dollar equivalent.
The Rise of GLP-1 Agonists: A Market Transformation
The most compelling narrative of FY2025 undoubtedly belongs to the glucagon-like peptide-1 (GLP-1) receptor agonists, which have transcended their original diabetes indications to become monumental players in the weight management market. Eli Lilly’s tirzepatide, under its brand names Mounjaro (for diabetes) and Zepbound (for weight loss), collectively demonstrated an astonishing performance. Mounjaro, already a significant force in FY2024 with $11.54 billion, nearly doubled its sales to $22.96 billion in FY2025, marking a 99.0% year-over-year increase. Its newer counterpart, Zepbound, which launched with high expectations, exceeded them dramatically, leaping from $4.93 billion to $13.54 billion, an astounding 174.9% growth. This combined performance positions tirzepatide as a formidable molecular entity, challenging the long-standing dominance of oncology treatments.
Novo Nordisk, a pioneer in the GLP-1 space, also solidified its market leadership. Ozempic, primarily for type 2 diabetes, continued its upward trajectory, reaching $19.21 billion with a 5.6% growth. However, it was Wegovy, Novo Nordisk’s dedicated weight-loss formulation of semaglutide, that showcased robust expansion, growing by 35.9% to achieve $11.96 billion in sales. The combined sales of semaglutide molecules (Ozempic, Wegovy, and the oral Rybelsus, which saw a slight decline to $3.34 billion) underscore the profound and rapidly expanding demand for these therapies.
Industry analysts have consistently pointed to the vast, untapped market for weight management and metabolic health as the primary driver behind this explosive growth. The efficacy of these drugs in achieving significant weight loss, alongside their cardiovascular benefits, has positioned them as transformative treatments. Pharmaceutical executives from both Eli Lilly and Novo Nordisk have frequently highlighted ongoing efforts to scale manufacturing capacity and navigate complex reimbursement landscapes, emphasizing their commitment to meeting burgeoning patient demand. The implications for public health are substantial, offering new hope for managing obesity and related comorbidities, though questions regarding long-term access, affordability, and healthcare system burden remain central to the ongoing discourse.
Oncology’s Enduring Strength: Keytruda Leads the Charge
Despite the meteoric rise of GLP-1s, immuno-oncology remains a cornerstone of pharmaceutical innovation and revenue. Merck’s Keytruda, a PD-1 inhibitor, continued its reign as the top-selling brand, posting $31.68 billion in FY2025 sales, a solid 7.5% increase from the previous year. Keytruda’s success is attributed to its ever-expanding list of indications across various cancers, from melanoma and lung cancer to head and neck squamous cell carcinoma and renal cell carcinoma. Its established position in first-line and adjuvant settings, combined with a robust clinical development program, ensures its continued leadership in the oncology space.
Bristol Myers Squibb’s Opdivo, another key PD-1 inhibitor, also demonstrated steady performance, growing by 8.0% to reach $10.05 billion. The persistent growth of these therapies underscores the ongoing prevalence of cancer and the critical role of immunotherapies in transforming patient outcomes. The oncology market continues to be a hotbed for research and development, with new modalities and combination therapies constantly emerging, ensuring that this therapeutic area will remain a significant revenue driver for the foreseeable future.
Immunologicals: A Powerhouse of Consistent Growth
The immunologicals category proved to be one of the most dynamic and consistently expanding therapeutic areas in FY2025, recording a collective growth of 20.6%. This segment addresses a broad spectrum of autoimmune and inflammatory conditions, including atopic dermatitis, psoriasis, psoriatic arthritis, Crohn’s disease, and multiple sclerosis, among others. Several drugs within this category posted substantial gains, indicating sustained unmet needs and successful market penetration.
Sanofi and Regeneron’s Dupixent, a blockbuster treatment for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, saw its sales climb by 20.2% to $17.74 billion, securing the 4th position overall. AbbVie’s Skyrizi, targeting psoriasis, psoriatic arthritis, and Crohn’s disease, exhibited impressive growth of 49.9%, reaching $17.56 billion and nearly matching Dupixent’s sales. AbbVie’s Rinvoq, a JAK inhibitor for similar indications, also surged by 39.1% to $8.30 billion.
Johnson & Johnson’s Darzalex, a treatment for multiple myeloma, achieved a 23.0% increase, bringing its sales to $14.35 billion. J&J’s Tremfya, indicated for psoriasis and psoriatic arthritis, also delivered robust growth of 40.5%, reaching $5.16 billion. Novartis’s Kisqali, an oncology drug that also saw significant growth (57.7% to $4.78 billion), and Cosentyx, an immunology drug (8.6% to $6.67 billion), further exemplify the diverse growth within specialty franchises.
The sustained expansion of immunologicals reflects several factors: the increasing diagnosis rates of autoimmune diseases, the high efficacy and improved safety profiles of newer biologics and targeted therapies, and the growing awareness among both patients and healthcare providers. Manufacturers in this space have invested heavily in R&D to broaden indications and develop next-generation therapies, signaling a continued commitment to this lucrative and impactful therapeutic area.
Other Notable Performers and Strategic Shifts
Beyond the top three therapeutic powerhouses, several other drugs and categories displayed significant activity in FY2025. Gilead Sciences’ Biktarvy continued its strong performance in HIV treatment, growing by 6.7% to $14.30 billion, maintaining its leadership in a critical public health domain. The cardiovascular segment saw mixed results; BMS/Pfizer’s Eliquis, an anticoagulant, posted a healthy 8.3% increase to $14.44 billion, while Novartis’s Entresto, for heart failure, experienced a slight dip of -0.9% to $7.75 billion, suggesting a maturing market for some established therapies.
In the diabetes and nephrology space, Boehringer Ingelheim/Lilly’s Jardiance grew by 4.8% to $9.93 billion, and AstraZeneca’s Farxiga/Forxiga expanded by 10.0% to $8.49 billion, underscoring the ongoing demand for advanced treatments in these chronic conditions. Pfizer’s Vyndaqel family, addressing rare diseases like transthyretin amyloid cardiomyopathy, also saw significant growth of 17.0% to $6.38 billion, highlighting the increasing importance of orphan drugs and specialized treatments.
Vaccines presented a varied picture. Pfizer’s Prevnar family of pneumococcal vaccines continued to be a strong performer with a 1.3% increase to $6.49 billion. However, Merck’s Gardasil, the HPV vaccine, experienced a substantial decline of -39.0% to $5.23 billion, potentially reflecting shifts in purchasing patterns or national immunization program timings.
The Impact of Biosimilars and Patent Expirations
A critical theme in FY2025 was the profound impact of patent expirations and the advent of biosimilars on formerly dominant blockbusters. This phenomenon led to significant revenue contractions for several long-standing pharmaceutical giants, underscoring the cyclical nature of drug lifecycles.
AbbVie’s Humira, once the world’s best-selling drug, saw its sales plummet by -49.5% to $4.54 billion. This dramatic decline is a direct consequence of multiple biosimilar entries into key markets, particularly in the United States, which eroded its market share. Similarly, Johnson & Johnson’s Stelara, another immunology powerhouse, experienced a substantial drop of -41.3% to $6.08 billion as it faced increasing biosimilar competition and market pressures.
Bristol Myers Squibb’s Revlimid, a prominent multiple myeloma drug, also saw its sales nearly halved, declining by -48.9% to $2.95 billion, due to generic erosion. The strategic implications for these companies are immense, necessitating robust pipeline development and new product launches to offset these revenue losses. This trend also benefits healthcare systems and patients by offering more affordable treatment options, though it places constant pressure on pharmaceutical companies to innovate and secure new intellectual property.
The Post-Pandemic Normalization
The normalization of the global health landscape post-COVID-19 also had a tangible effect on drug sales. Pfizer/BioNTech’s Comirnaty, the mRNA COVID-19 vaccine, continued its decline, falling by -18.4% to $4.37 billion. Similarly, Pfizer’s Paxlovid, the antiviral treatment for COVID-19, experienced an even steeper drop of -58.7% to $2.36 billion. These figures reflect the shift from a pandemic emergency response to an endemic management approach, with reduced demand for mass vaccination and acute treatment, though these products remain important tools in public health arsenals.
Emerging Leaders and the Future Pipeline
Looking beyond the immediate top sellers, several drugs demonstrated impressive growth rates in FY2025, signaling their potential to become future blockbusters. Novartis’s Kisqali (up 57.7%), J&J’s Tremfya (up 40.5%), BMS’s Reblozyl (up 31.2%), GSK/ViiV’s Cabenuva (up 38.4%), and BMS’s Breyanzi (up 81.8%), Opdualag (up 27.7%), and Camzyos (up 77.4%) all showcased significant momentum. These drugs span oncology, rare blood disorders, HIV, and cardiovascular conditions, illustrating the diverse areas of active pharmaceutical innovation.
The observation that the overall pharma pipeline contracted in FY2025, even as specific therapeutic buckets expanded, suggests a more focused and perhaps more challenging R&D environment. Companies might be prioritizing assets with higher probability of success or larger market potential, leading to a leaner but potentially more impactful pipeline.
Broader Industry Implications
The FY2025 Pharma 50 report offers crucial insights into the evolving pharmaceutical landscape. The dominance of GLP-1 agonists underscores a monumental shift towards metabolic health and weight management as primary therapeutic targets, potentially revolutionizing how chronic diseases are managed globally. This rise will undoubtedly trigger further R&D investment, competitive pressures, and intense scrutiny over pricing and market access.
The sustained strength of oncology and immunologicals reaffirms the industry’s commitment to addressing complex diseases with high unmet needs, driven by continuous scientific breakthroughs. However, the dramatic declines of drugs facing biosimilar competition highlight the ongoing "patent cliff" challenge and the imperative for companies to maintain a robust and innovative pipeline.
The geopolitical and regulatory environment also plays a crucial role, with global health priorities, market access negotiations, and evolving regulatory pathways influencing drug development and commercialization strategies. As pharmaceutical companies navigate these complex dynamics, the focus will remain on delivering high-value therapies that address significant patient needs while ensuring sustainable growth and innovation for the future. The data for FY2025 paints a picture of an industry that is both dynamic and resilient, constantly adapting to scientific advancements, market demands, and global health challenges.
Leave a Reply